1bf shows better activity (IC 50 = 4.56 µM) than EPZ004777 (IC 50 = 35.19 µM). Intermediate 9a displays good activity (IC 50 = 29.98 µM) and acceptable cytotoxicity (CC 50 > 200 µM). ABSTRACT: We report herein the design and synthesis of a series of novel Sinefungin (SIN) derivatives, based on the structures of SIN and its analogue EPZ004777. Our results reveal that target compounds 1ad-af, 1ba-bb and 1bf-bh show better activity (IC 50 = 4.56-20.16 µM) than EPZ004777 (IC 50 = 35.19 µM). Surprisingly, SIN was founded to be not as active (IC 50 > 50 µM) as we and other research groups predicted. Interestingly, the intermediates 9a-b and 11b display potent anti-ZIKV potency (IC 50 = 6.33-29.98 µM), and compound 9a also exhibits acceptable cytotoxicity (CC 50 > 200 µM), suggesting their promising potential to be leads for further development.
) was isolated from the fermentation broth of Streptomyces griseoleus NRRL 3739 by Eli Lilly as a potential antifungal antibiotic. [7] [8] It is structurally similar to S-Adenosyl methionine (SAM) and acts as a competitive inhibitor of numerous Methyltransferases (Mtases). It was reported that SIN exhibited antitumor, [9] antiviral [10] [11] and antiparasitic activity [12] . Recently, SIN was demonstrated to show considerable anti-flavivirus activity (WNV, DENV-2 and YFV). Since ZIKV belongs to the flavivirus family, we agreed with others [13] [14] [15] in speculating that SIN might also be a potential ZIKV inhibitor. substituent is fluorine, compounds 1ad-af with 4-t-Bu-phenyl, 4-CF 3 -phenyl and 3-CF 3 -phenyl as the aryl W group show excellent anti-ZIKV potency (IC 50 = 6.46-6.99 µM). In contrast, introduction of other aryl W substituents leads to a compete loss of activity (1aa-ac and 1ag-ah, IC 50 > 50 µM). When the aryl X substituent is chlorine, apart from a few exceptions (1bc-be), all of these compounds display potent activity (IC 50 < 30 µM), and the contribution of aryl W group to the activity is in this order: 3-CF 3 -phenyl > 4-Me-phenyl > cyclohexyl > 4-F-phenyl > t-Bu > 4-methoxyphenyl. Subsequently, intermediates 9-12 were tested for their anti-ZIKV activity ( Table 2 ). Most of the intermediates 10a-b, 11a and 12a-b are not active (IC 50 > 50 µM) but 9a, 9b and 11b (IC 50 = 6.33-29.98 µM) fortunately display potent anti-ZIKV activity. Among them, compound 9b (IC 50 = 6.33 µM) demonstrated to be more potent than its fluorne analogue 10a. Interestingly, this SAR is similar as above in the SIN derivatives. 
Cytotoxicity
The SIN derivatives and additional intermediates that displayed considerable anti-ZIKV activity (IC 50 < 50 µM) were further evaluated for cytotoxicity test against BHK cell line by Cell Titer-Glo Luminescent Cell Viability Assay (Promega) . Unfortunately, all the tested SIN derivatives (CC 50 = 5.88-58.49 µM) exhibit higher cytotoxicity than EPZ004777 (CC 50 > 200 µM), and their selective indexes (SI = 1.29-4.70) are lower than EPZ004777 (SI > 5.68). The best compound 1bf displays the highest cytotoxicity (CC 50 = 5.88 µM), the least 1bg also exhibits the lowest cytotoxicity (CC 50 = 58.49 µM). Considering both of the activity and cytotoxicity, compound 1bh which holds the highest selective index (SI = 4.70) among these analogues could be selected as a lead compound for further modification.
To our delight, we observed that compound 9a shows acceptable cytotoxicity (CC 50 > 200 µM) and potent anti-ZIKV activity (IC 50 = 29.98 µM), suggesting compound 9a might be a potent M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT candidate for further development. Compounds 9b and 11b with higher cytotoxicity (CC 50 = 29.39-70.61 µM) deserve further modification in the future.
Conclusion
In summary, the natural product SIN was selected as our lead compound but proved to be inactive in this study, whereas its structural analogue EPZ004777 displays considerable anti-ZIKV activity (IC 50 = 35.19 µM) . A series of structural unique SIN derivatives with a 3-fluoro or chloro-benzyl group and a lipophilicity side chain were designed, synthesized and evaluated for anti-ZIKV activity. SIN derivatives 1ad-af, 1ba-bb, and 1bf-bh show more potent activity µM) than EPZ004777, but their CC 50 values are lower than EPZ004777 (CC 50 > 200 µM). We also observed that intermediates 9a-b and 11b display potent anti-ZIKV activity (IC 50 = 6.33-29.98 µM). These intermediates, possessing a simplified structure, could be selected as new lead compounds for further studies. In addition, we found that compound 9a displays acceptable cytotoxicity (CC 50 > 200 µM), suggesting its promising potential as a candidate for further development. Studies to determine the in vivo efficacy of 9a are currently underway. H NMR spectra were determined on a Varian Mercury-400 or Bruker 500 M spectrometer in MeOD or CDCl 3 using tetramethylsilane as an internal standard. Electrospray ionization (ESI) mass spectra was obtained on an Agilent 1260-6420 Mass spectrum instruments. The reagents were all of analytical grade or chemically pure. TLC was performed on silica gel plates (Merck, ART5554 60F254). All the anhydrous solvents were purchased from J&K Scientific.
Synthesis

4.2.1.
((3aR,4R,6R,6aR)-6-(6-((3-fluorobenzyl)amino)-9H-purin-9-yl)-2,2-dimethyl tetrahydrofuro [3,4-d] [1, 3] 
To a stirred solution of compound 2 (3 g, 9.2 mmol) 7.79 (s, 1H, 1H, 7.17 (d, J = 7.5 Hz, 1H, 7.11 (d, J = 9 Hz, 1H, 6.59 (brs, 1H, NH), 5.89 (s, 1H, 5.24 (t, J = 5.1 Hz, 1H, 5.14 (d, J = 5.5 Hz, 1H, ((3aR,4R,6R,6aR)-6-(6-((3-chlorobenzyl)amino)-9H-purin-9-yl)-2,2-dimethyl tetrahydrofuro [3,4-d] [1, 3] dioxol-4-yl)methanol 3b
Following above synthetic procedure of compound 3a, [3,4-d] [1, 3] 
To a stirred solution of compound 3a (1 g, 2.4 mmol) in THF (20 mL) was added Ph 3 P (1.26 g, 4.8 mmol), DIAD (0.94 mL, 4.8 mmol) and phthalimide (0.53 g, 3.6 mmol) at room temperature. The mixture was stirred for 3 hours and concentrated. The residue was purified by column chromatography over silica gel (DCM : MeOH : NH 3 H 2 O = 200 : 10 : 0.1) to yield a brown oil, which was used directly for the next step.
To a stirred solution of above oil in EtOH (50 mL) was added hydrazine hydrate (1 mL) at room temperature. The mixture was refluxed for 2 hours and filtered. The filtrate was concentrated. The residue was purified by column chromatography over silica gel (DCM : MeOH : NH 3 H 2 O = 100 : 10 : 0.2) to yield compound 4a (680 mg, 68%) as a colorless oil, 1 
To a stirred solution of compound 4a (1 g, 2.4 mmol) in MeOH (30 mL) was added acetone (3 mL) and NaCNBH 3 (0.6 g, 9.6 mmol) at room temperature. The mixture was stirred for 15 minutes, adjusted to pH 7 by acetic acid. The mixture was stirred 4 hours at the same temperature, quenched by 1M NaOH solution (10 mL 
4.2.6.
N-(3-chlorobenzyl)-9-((3aR,4R,6R,6aR)-6-((isopropylamino)methyl)-2,2-dimethyl tetrahydrofuro [3,4-d] [1, 3] dioxol-4-yl)-9H-purin-6-amine 5b
Following above synthetic procedure of compound 5a, replacing 4a with 4b afforded compound 5b (75%) as an oil, LRMS (ESI): m/z = 473 [M + H] + .
4.2.7.
methyl 3-((((3aR,4R,6R,6aR)-6-(6-((3-fluorobenzyl)amino)-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro [3 ,4-d] [1, 3] dioxol-4-yl)methyl)(isopropyl)amino)propanoate 6a A solution of 5a (1 g, 2.2 mmol) and methyl acrylate (0.4 mL) in MeOH (10 mL) was sealed in a microwave tube, heated to 90 o C under microwave radiation for 3 hours. The mixture was concentrated and purified by column chromatography over silica gel (DCM : MeOH = 40 : 1) to yield compound 6a (0.9 g, 76%) as an oil, 1 
Following above synthetic procedure of compound 6a, replacing 5a with 5b afforded compound 6b (80%) as an oil, LRMS (ESI): m/z = 559 [M + H] + .
To a stirred solution of 6a (900 mg, 1.66 mmol) in anhydrous THF (10 mL 3-((((3aR,4R,6R,6aR)-6-(6-((3-chlorobenzyl)amino)-9H-purin-9-yl)-2,2-dimethyl tetrahydrofuro [3,4-d] [1, 3] dioxol-4-yl)methyl)(isopropyl)amino)propan-1-ol 7b
Following above synthetic procedure of compound 7a, replacing 6a with 6b afforded compound 7b (85%) as an oil, LRMS (ESI): m/z = 531 [M + H] + .
Following above synthetic procedure of compound 4a, replacing 3a with 7a afforded crude 8a (80% percent pure from LC-MS, yield 76%) which was used directly for the next step without further purification, LRMS (ESI): m/z = 514 [M + H] + . To a stirred solution of 8a-b (0.15 mmol) in acetonitrile (5 mL) was added isocyanate (0.2 mmol) at room temperature. The mixture was stirred for 1 hour and concentrated. The residue was purified by column chromatography over silica gel (DCM : MeOH = 20 : 1) to yield an oil.
To a stirred solution of above solid in DCM (6 mL) was added TFA (1 mL According to the general procedure, employing 8b and 1-isocyanato-4-methoxylbenzene afforded compound 1ba as a solid, 75% yield, HPLC purity: 99.6%, method A; mp: [189] [190] [191] 8.22 (s, 1H, 3H, 3H, 2H, 6.13 (brs, 1H, NH), 5.88 (d, J = 6.9 Hz, 1H, 5.44 (d, J = 7.4 M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
Hz, 1H, tetrahydrofuran-H), 5.18 (d, J = 5.8 Hz, 1H, 3H, 4.15 (brs, 1H , CH 2 -1H), 3.93 (brs, 1H, CH 2 -1H), 3.08-3.06 (m, 2H, CH 2 ), 1H, 1H, NH), 2H, CH 2 4.2.13.10. 1-(3-((((2R,3S,4R,5R)-5-(6-((3-chlorobenzyl) 
According to the general procedure, employing 8b and 1-isocyanato-4-methylbenzene afforded compound 1bb as a solid, 65% yield, HPLC purity: 92.0%, method A; mp: 180-181 o C; [α] 20 D = 13.69 (c 0.45, MeOH); 1 H NMR (500 MHz, MeOD) δ 8.30 (s, 1H, purin-H), 8.18 (s, 1H, 7.41 (s, 1H, 3H, 7.20 (d, J = 8.8 Hz, 2H, 4.2.13.11. 1-(3-((((2R,3S,4R,5R)-5-(6-((3-chlorobenzyl) amino)-9H-purin-9-yl)-3,4-dihydroxy tetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)-3-(4-methoxyphenyl)urea 1bc
According to the general procedure, employing 8b and 1-isocyanato-4-methoxylbenzene afforded compound 1bc as a solid, 77% yield, HPLC purity: 93.6%, method A; mp: 170- 
HPLC purity determination
All samples were performed on an Agilent 1260 HPLC-UV system, using Method A, B, or C as follows. Solvent A = Acetonitrile; solvent B = Tetramethylammonium hydroxide solution, solvent C = Methonal; column (Waters Xterra RP18, 4.6 mm × 250 mm, 5 µm), 40 o C; UV at 254 nm.
Preparation of solvent B：To a stirred solution tetramethylammonium hydroxide (4.53 g) in H 2 O (1000 mL) was added triethylamine (0.1 mL), and then adjusted to pH 9.0 by phosphoric acid.
Method A: Solvent A : Solvent B = 50 : 50, flow: 0.7 mL/min, 16 min; Method B: Solvent A : Solvent B = 50 : 50, flow: 1.5 mL/min, 16 min; Method C: Solvent C : Solvent B = 60 : 40, flow:1.2 mL/min, 20 min.
Anti-ZIKV Assay
The reference drug Sinefungin and EPZ004777 were purchased from STEMCELL Technologies. The ZIKV was obtained from the Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
BHK cells were seeded into 96-well plate using DMEM supplemented with 10% FBS and penicillin and streptomycin (100 units/ml and 100 µg/ml, respectively) at a density of 5,000 cells per well. After 24 h incubation at 37 with 5% CO ℃ 2 , original medium was changed into maintenance medium (DMEM supplemented with 2% FBS and P/S) in a volume of 100 µL. Zika virus stocks propagated in Vero cells were diluted to 100TCID 50 and added 50 µL to each virus control and administered well. The compounds that diluted from 50 µM by 3-fold dilution in maintenance medium were added to administered wells. The wells were supplemented with maintenance medium to 200 µL. The plates were incubated for 8 days until the CPE reached 100%. The cell viability was measured by Cell Titer-Glo® luminescent cell viability kit according to the manufacturer's instructions. The IC 50 values were calculated by Origin 8.0.
Cytotoxicity determination
Various concentrations of compounds from 200 µM to 0.09 µM by 3-fold dilution were diluted in maintenance medium. BHK cells were seeded in 96-well plate at a density of 5,000 cells per well and allowed to recover for 24 h. Culture medium was replaced by maintenance medium containing the compound to be examined or drug-free. After 8 days' exposure, cell viability was also determined with Cell Titer-Glo reagent. The CC 50 values were calculated by Origin 8.0.
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